Leadership & Pay ·
TELA Bio announced a strategic cost reduction initiative to preserve capital and extend its cash runway into 2028
TELATELA Bio, Inc.
TELA Bio announced a strategic cost reduction initiative to preserve capital and extend its cash runway into 2028. The company is reducing its workforce by approximately 20%, from 201 to 160 full-time employees, aiming to lower annual operating expenses by $17.0 million. This restructuring involves a one-time charge of approximately $1.5 million for severance and related costs, expected to be substantially completed in the third quarter of 2026. Concurrently, Roberto Cuca stepped down as Chief Financial Officer and Chief Operating Officer effective August 31, 2026, due to termination without cause under his employment agreement. Heather Getz was appointed as the new principal financial officer. TELA Bio operates in the medical technology industry, providing soft-tissue reconstruction solutions.